xMAP® SARS-CoV-2 Multi-Antigen IgG Assay (RUO)
The xMAP® SARS-CoV-2 Multi-Antigen IgG Assay is a serological, multiplexed microsphere-based assay to measure the presence of IgG antibodies directed against the nucleocapsid protein (N), Receptor-Binding Domain (RBD) of the spike protein, and the S1 subunit of the spike protein (S1) of SARS-CoV-2 in human serum or plasma. The xMAP SARS-CoV-2 Multi-Antigen IgG Assay features: Broad Coverage: Detects IgG antibodies aga…
The supplier does not provide quotations for this product through SelectScience. You can search for similar products in our Product Directory.
The xMAP® SARS-CoV-2 Multi-Antigen IgG Assay is a serological, multiplexed microsphere-based assay to measure the presence of IgG antibodies directed against the nucleocapsid protein (N), Receptor-Binding Domain (RBD) of the spike protein, and the S1 subunit of the spike protein (S1) of SARS-CoV-2 in human serum or plasma.
The xMAP SARS-CoV-2 Multi-Antigen IgG Assay features:
- Broad Coverage: Detects IgG antibodies against 3 SARS-CoV-2 antigens, providing comprehensive results:
- S1 subunit of the spike protein
- Receptor Binding Domain (RBD) of the spike protein
- Nucleocapsid protein
- Flexible Throughput: Test up to 96 samples per run in less than 3 hours to meet your throughput needs.
- Versatile System Options: Can be used on MAGPIX®, Luminex® 200™, and FLEXMAP 3D® Systems, so you can use the platform that best fits your lab.
- Common Sample Types: Designed for use with plasma and serum samples, eliminating the need to implement additional collection protocols.
For Research Use Only. Not for use in diagnostic procedures.
